Greater Salzburg
Commercial and operational leader in biologics and CDMO with 15+ years of experience driving growth, strategic partnerships, and international expansion. Currently leading contract manufacturing, business development, and external supply at EVER Pharma, with P&L responsibility. Selected highlights: - Doubled CDMO business and trippled EBIT margin - Built external supply organization contributing ~20% of company revenue - Led international expansion through licensing, partnerships, and M&A Background across Samsung Biologics, Novartis, and Sandoz, combining biologics manufacturing expertise with strong commercial execution.
Own and lead contract manufacturing (CDMO), business development, and external supply functions with full P&L responsibility Key achievements: - Scaled CDMO business revenue and expanded EBIT margin - Secured multi-year global CDMO agreements generating incremental annual revenue - Built and led external supply organization managing products contributing ~20% of total company revenue - Directed strategic product transfers and portfolio optimization initiatives - Led international M&A evaluations and post-merger integration to support expansion - Established global partnerships through licensing and long-term manufacturing agreements
Led supplier management and program execution for a $150M+ oncology injectables portfolio across global CMOs. - Managed ~$20M external manufacturing spend and improved supplier performance and reliability - Led cross-functional task force (30+ stakeholders) resolving critical compliance issue and preventing global supply disruption - Directed product launches and site transfers across Europe and Asia
Led global strategic planning and portfolio optimization for oncology injectables business. - Delivered ~$30M cost savings through portfolio rationalization and network optimization - Developed roadmap to scale business toward $1B revenue - Executed site consolidation and capacity reallocation to higher-value manufacturing
Led European business development and global marketing initiatives for Samsung Biologics, supporting market entry and rapid expansion of its biologics CDMO business. Key achievements: - Identified and negotiated $2B+ in CDMO opportunities with global pharmaceutical and biotech clients - Built strategic client base across Europe and MEA, targeting top-tier pharma companies and emerging biotech firms - Developed and executed global marketing strategy positioning Samsung Biologics as a leading biologics CDMO - Established key partnerships enabling rapid scale-up of manufacturing capacity and commercial footprint - Played a central role in building the commercial foundation for Samsung Biologics’ successful global market entry